Managing the Impact of Immunogenicity in an Era of Immunotherapy: From Bench to Bedside-Reference-Cited by-同舟云学术

Managing the Impact of Immunogenicity in an Era of Immunotherapy: From Bench to Bedside

Published:2021-07 Issue:7 Volume:110 Page:2575-2584
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Bray-French Katharine,Hartman Katharina,Steiner Guido,Marban-Doran Céline,Bessa Juliana,Campbell Neil,Martin-Facklam Meret,Stubenrauch Kay-Gunnar,Solier Corinne,Singer Thomas,Ducret Axel^ORCID

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference89 articles.

1. Evaluating and mitigating the immunogenicity of therapeutic proteins;Sauna;Trends Biotechnol,2018

2. Immunogenicity of protein pharmaceuticals;Dingman;J Pharm Sci,2019

3. From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals;Gunn;Clin Exp Immunol,2016

4. Immunogenicity of biotherapeutics: causes and association with posttranslational modifications;Kuriakose;J Immunol Res,2016

5. American association of pharmaceutical S. assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations;Shankar;AAPS J,2014

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Workshop report: A study roadmap to evaluate the safety of recombinant human lactoferrin expressed in Komagataella phaffii intended as an ingredient in conventional foods – Recommendations of a scientific expert panel;Food and Chemical Toxicology;2024-08

2. A review of the safety evidence on recombinant human lactoferrin for use as a food ingredient;Food and Chemical Toxicology;2024-07

3. Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure;Frontiers in Oncology;2024-03-21

4. Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors;Clinical Cancer Research;2024-02-06

5. In vivo study of newly developed albumin-conjugated urate oxidase for gout treatment;Arthritis Research & Therapy;2023-12-18